Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab

Sébastien Baechler, Robert F. Hobbs, Heather A. Jacene, François O. Bochud, Richard L. Wahl, George Sgouros

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Predicting hematologic toxicity in patients undergoing radioimmunotherapy with <sup>90</sup>Y-ibritumomab tiuxetan or <sup>131</sup>I-tositumomab'. Together they form a unique fingerprint.

Medicine & Life Sciences